Poly Medicure Limited has rescheduled its one-on-one virtual meeting with Wasatch Global to August 27, 2026. The company disclosed the change in a filing dated August 25, 2026, noting that the confirmation was received on shorter notice.

The engagement is held pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III Part A. Poly Medicure stated that no unpublished price-sensitive information would be shared during the interaction.

Updated Meeting Schedule

The session with Bajaj Alternative Investment Ltd remains unchanged for August 20. The meeting with Wasatch Global, previously cancelled, is now confirmed for the following week.

The venue and format for the Wasatch Global meeting remain virtual and one-on-one. Poly Medicure noted that the schedule is subject to change due to exigencies on the part of analysts, investors, or the company.

Poly Medicure Limited has scheduled one-on-one meetings with analysts and investors for August 27 and August 31, 2026. The engagements are part of the company’s ongoing disclosure obligations under SEBI regulations.

The company notified the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the schedule. These interactions aim to provide market participants with updates on the business, subject to regulatory guidelines.

Meeting Schedule

The management team will host two separate sessions during the latter half of August. One meeting is virtual, while the other will be held at the registered office in New Delhi.

Regulatory Compliance

The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates timely disclosure of price-sensitive information to stock exchanges.

Avinash Chandra, Company Secretary, signed the communication. He confirmed that no unpublished price-sensitive information will be shared during these meetings. The schedule remains subject to change due to exigencies on the part of the analysts, investors, or the company.

Investors can access further details on the company’s website.